Distribution of Lipoprotein-Associated Phospholipase A2 in Czech Population and its interaction with conventional cardiovascular risk
Abstract
Lipoprotein-associated phospholipase A2 (Lp- PLA2) represent new cardiovascular risk factor and potential treatment target. We aimed to analyze the epidemiological situation of this factor in Czech population.
Methods and Results: The study population consisted from 1 962 subjects, a random samples of general population (postMONICA study), and from patients with manifest coronary or cerebrovascular disease (Czech samples of EUROASPIRE III survey). Lp- PLA2 activity was estimated using commercial kits by diaDexus Inc. in frozen samples.
Increased activity (by defi nition, i.e. > 195 nmol/ min/ ml) was observed in 21.1 % of sample, no apparent difference between subject with and without manifest vascular disease was found. Males showed higher Lp- PLA2 activity, than females (179.6 vs 146, resp., p 195 as dependent variable, following independent variables entered the multiple logistic regression: male gender [with odds ratio 4.26 (3.26– 5.58)], low HDL-cholesterol (i.e. 2.5 mmol/ l [6.95 (4.79– 10.07)] and lipid- lowering treatment [0.59 (0.44– 0.79)].
In subject without manifest vascular disease, 6.3 % of them showed co- incidence of markedly increased Lp- PLA2 activity with high conventional risk (SCORE > 10 %). Expanding this group by intermediate risk subjects (ie. with Lp- PLA2 activity 152– 194 and/ or SCORE 5– 9.9 %) leads to increase of this prevalence to 28.9 % of primary prevention subjects.
Conclusion: Increased Lp- PLA2 activity is in Czech population highly prevalent and with exception of lipid parameters, generally independent from conventional cardiovascular risk. However, up to 29 % of subject in primary prevention amalgamate increased Lp- PLA2 activity with high conventional cardiovascular risk.